Katharina Kieslich1,*, Jesse B. Bump2 , Ole Frithjof Norheim3 , Sripen Tantivess4 and Peter Littlejohns1 1 Faculty of Life Sciences & Medicine, Division of Health and Social Care Research, King’s College London, London, UK 2 Department of Global Health and Population, Harvard T. H. Chan School o

GIULIA GRECOa,*, PAULA LORGELLYb and INTHIRA YAMABHAIc a London School of Hygiene & Tropical Medicine, London, UK b Centre for Health Economics, Monash University, Melbourne, Victoria, Australia c Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Bangko

Yot Teerawattananon, Alia Luz* , Songyot Pilasant, Suteenoot Tangsathitkulchai, Sarocha Chootipongchaivat, Nattha Tritasavit, Inthira Yamabhai and Sripen Tantivess Abstract Background: It is very challenging for resource-limited settings to introduce universal health coverage (UHC), particular

Waranya Rattanavipapong1, Alia Cynthia Gonzales Luz1,*, Suthasinee Kumluang1,Nunik Kusumawardani2 and Yot Teerawattananon1 Co-investigators: Dewi Indriani3, Priska Apsari Primastuti3, Lily Banonah Rivai4, Sri Idaiani2, Ully Adhie2, Thunyarat Anothaisintawee1, Sarocha Chootipongchaivat1, Kanlaya T

Improving quality of primary care through financial incentives: the case of Thailand. Paramjit Gill1, Rachel Foskett-Tharby1, Francoise Cluzeau2, Sripen Tantivess3 and Yot Teerawattananon3 1National Collaborating Centre for Indicator Development, University of Birmingham, UK 2NICE International

K. Chittawatanarat a, *, K. Tosanguan b, U. Chaikledkaew b, c, S. Tejavanija d, Y. Teerawattananon b a Division of Trauma and Critical Care, Department of Surgery, Faculty of Medicine, Maharaj Nakorn Chiang Mai Hospital, Intawarorod Road, Sripume, Chiang Mai University, Chiang Mai 50200, Thailand

Siriporn Pooripussarakul1, Arthorn Riewpaiboon1* , David Bishai2, Charung Muangchana3 and Sripen Tantivess4 Abstract Background: There is a need to identify rational criteria and set priorities for vaccines. In Thailand, many licensed vaccines are being considering for introduction into the Ex

Kittiphong Thiboonboon1 , Benjarin Santatiwongchai1 ,Varit Chantarastapornchit1 , Waranya Rattanavipapong1 , Yot Teerawattananon1 Abstract Background For more than three decades, the number and influence of economic evaluations of healthcare interventions have been increasing and gaining atte

Objective: Implementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis